Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | NPC1 | O15118 | 3/20 | 0.39 |
| ▸ | RAB9A | P51151 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | MITF | O75030 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | SETD7 | Q8WTS6 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | FAAH | O00519 | 2/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
| ▸ | SLC9A1 | P19634 | 3/20 | 0.33 |
| ▸ | MIF | P14174 | 1/20 | 0.33 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14841639 | 0.79 | CA12 (0.35) | ALDH1A1NPC1RAB9AMEN1MAPT | |
| SCHEMBL8706453 | 0.78 | — | — | |
| SCHEMBL1661344 | 0.78 | CHRM2 (0.33) | MEN1KMT2APTGS1 | |
| SCHEMBL2638049 | 0.74 | KDM4E (0.34) | ALDH1A1MEN1MAPTKMT2A | |
| SCHEMBL1661412 | 0.71 | BRD4 (0.34) | ALDH1A1MEN1MAPTKMT2A | |
| SCHEMBL1274347 | 0.70 | CASP3 (0.33) | ALDH1A1MAPTSMN1; SMN2L3MBTL1 | |
| SCHEMBL8596193 | 0.68 | ALDH1A1 (0.39) | ALDH1A1NPC1RAB9AMEN1MAPT | |
| SCHEMBL24916174 | 0.66 | — | — | |
| SCHEMBL9830527 | 0.66 | SETD7 (0.38) | ALDH1A1NPC1RAB9AMEN1MAPT | |
| SCHEMBL21899737 | 0.65 | FDPS (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240100023-A1 | Compositions and Methods For Treating Spinal Cord Injuries | LIPPA ARNOLD S (US) | 2024-03-28 | — | — | US | claimed |
| US-20230373982-A1 | Compositions And Methods For Treating Attention Deficit Disorders | LIPPA ARNOLD STAN (US) | 2023-11-23 | — | — | US | claimed |
| US-20230129330-A1 | Compositions And Methods For Treating Attention Deficit Disorders | LIPPA ARNOLD STAN (US) | 2023-04-27 | — | — | US | claimed |
| US-20210340130-A1 | Compositions and methods for treating attention deficit disorders | LIPPA ARNOLD STAN (US) | 2021-11-04 | — | — | US | claimed |
| US-20190112300-A1 | Compositions And Methods For Treating Attention Deficit Disorders | LIPPA ARNOLD STAN (US) | 2019-04-18 | — | — | US | claimed |
| EP-3436021-A1 | COMPOSITIONS AND METHODS FOR TREATING ATTENTION DEFICIT DISORDERS | RespireRx Pharmaceuticals Inc. (US) | 2019-02-06 | — | — | EP | claimed |
| WO-2018009256-A1 | COMPOSITIONS AND METHODS FOR TREATING ATTENTION DEFICIT DISORDERS | RESPIRERX PHARMACEUTICALS, INC. (US) | 2018-01-11 | — | — | WO | claimed |
| EP-2297222-B1 | POLYMERIZABLE COMPOSITION CONTAINING INORGANIC PARTICLES HAVING AN ORGANIC SHELL | HENKEL AG & CO KGAA (DE) | 2011-11-02 | — | — | EP | claimed |
| US-20240100023-A1 | Compositions and Methods For Treating Spinal Cord Injuries | LIPPA ARNOLD S (US) | 2024-03-28 | — | — | US | disclosed |
| US-20230373982-A1 | Compositions And Methods For Treating Attention Deficit Disorders | LIPPA ARNOLD STAN (US) | 2023-11-23 | — | — | US | disclosed |
| US-20230129330-A1 | Compositions And Methods For Treating Attention Deficit Disorders | LIPPA ARNOLD STAN (US) | 2023-04-27 | — | — | US | disclosed |
| US-20220142960-A1 | Compositions and Methods for Treating Metabolic Disorders | VEROSCIENCE LLC | 2022-05-12 | — | — | US | disclosed |
| US-20210340130-A1 | Compositions and methods for treating attention deficit disorders | LIPPA ARNOLD STAN (US) | 2021-11-04 | — | — | US | disclosed |
| US-20210308111-A1 | Clinical Methods And Pharmaceutical Compositions Employing AMPA Receptor Antagonists To Treat Glioblastoma And Other Cancers | WITH GREAT POWER LLC (US) | 2021-10-07 | — | — | US | disclosed |
| EP-1067935-A4 | ACYLBENZOXAZINES FOR ENHANCING SYNAPTIC RESPONSE(S) | UNIV CALIFORNIA (US) | 2001-10-04 | — | — | EP | disclosed |
| CN-1306427-A | Acylbenzoxazines for enhancing synaptic response(s) | UNIV CALIFORNIA (US) | 2001-08-01 | — | — | CN | disclosed |
| EP-1067935-A1 | ACYLBENZOXAZINES FOR ENHANCING SYNAPTIC RESPONSE(S) | The Regents of the University of California (US) | 2001-01-17 | — | — | EP | disclosed |
| US-6124278-A | COGNITION ACTIVATORS FOR LEARNING/MEMORY ENHANCEMENT AND TREATMENT OF BRAIN/PSYCHOLOGICAL DISORDERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2000-09-26 | — | — | US | disclosed |
| US-6124278-A | COGNITION ACTIVATORS FOR LEARNING/MEMORY ENHANCEMENT AND TREATMENT OF BRAIN/PSYCHOLOGICAL DISORDERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2000-09-26 | — | — | US | disclosed |
| WO-1999051240-A1 | ACYLBENZOXAZINES FOR ENHANCING SYNAPTIC RESPONSE(S) | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1999-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210340130-A1 | Compositions and methods for treating attention deficit disorders | GRIN2A, GRIN2C, GRM2 | ALDH1A1 1104/4885NPC1 1767/4885RAB9A 2388/4885 |
| US-20240100023-A1 | Compositions and Methods For Treating Spinal Cord Injuries | CHAT, NTRK2, GMFG | ALDH1A1 581/4885NPC1 3127/4885RAB9A 2165/4885 |
| US-20230129330-A1 | Compositions And Methods For Treating Attention Deficit Disorders | GRIN2A, GRIN2C, GRM2 | ALDH1A1 1104/4885NPC1 1767/4885RAB9A 2388/4885 |
| US-20210308111-A1 | Clinical Methods And Pharmaceutical Compositions Employing AMPA Receptor Antagonists To Treat Glioblastoma And Other Cancers | GRM2, GRM1, GRIN1 | ALDH1A1 2307/4885NPC1 3790/4885RAB9A 2173/4885 |
| US-20230373982-A1 | Compositions And Methods For Treating Attention Deficit Disorders | GRIN2A, GRIN2C, GRM2 | ALDH1A1 1104/4885NPC1 1767/4885RAB9A 2388/4885 |
| US-20190112300-A1 | Compositions And Methods For Treating Attention Deficit Disorders | GRIN2A, GRIN2C, GRM2 | ALDH1A1 1104/4885NPC1 1767/4885RAB9A 2388/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.